![]() |
|
|
Vol. 286, Issue 3, 1231-1238, September 1998
Department of Neuropharmacology, Dopamine neurotransmission is an important neuropharmacological
component of cocaine self-administration in rodents. Terguride is a
prototype drug belonging to a recently characterized class of
compounds, dopamine partial agonists, which appear to possess a unique
pharmacological profile in altering dopamine neurotransmission, where
these drugs act as antagonists in conditions of high dopaminergic tone.
The aim of the present study was therefore to test the effects of
systemic administration of terguride in rats self-administering cocaine
intravenously. The different aspects of cocaine self-administration examined after treatment with terguride were (a) the acute reinforcing properties of cocaine in rats exposed to limited-access
self-administration of cocaine, (b) a full cocaine dose-effect
function, (c) the reinforcing properties of cocaine as measured by a
progressive ratio schedule and (d) the ability of terguride to maintain
self-administration by itself. Terguride (0.025-0.4 mg/kg i.p.)
significantly and dose-dependently reduced the acute reinforcing
properties of cocaine as measured by an increase in responding for a
single training dose of cocaine and a reduction of the
inter-reinforcement interval. In addition, terguride (0.2-0.4 mg/kg)
shifted the entire cocaine dose-effect function to the right, thus
showing an antagonism of the reinforcing properties of cocaine
independent of response rate. Moreover, in rats trained to
self-administer cocaine on a progressive ratio schedule, terguride
reduced the maximum fixed ratio ("breaking point") for cocaine
reinforcement, also suggesting a decrease in the reinforcing properties
of cocaine. Finally, in rats trained to self-administer cocaine
terguride did not substitute for cocaine, thus indicating that
terguride does not maintain intravenous self-administration by itself.
0022-3565/98/2863-1231$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
J. Treweek, S. Wee, G. F. Koob, T. J. Dickerson, and K. D. Janda Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease PNAS, July 10, 2007; 104(28): 11580 - 11584. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Gyertyan, B. Kiss, K. Gal, I. Laszlovszky, A. Horvath, L. I. Gemesi, K. Saghy, G. Pasztor, M. Zajer, M. Kapas, et al. Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1268 - 1278. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. V. Khroyan, R. L. Barrett-Larimore, J. K. Rowlett, and R. D. Spealman Dopamine D1- and D2-Like Receptor Mechanisms in Relapse to Cocaine-Seeking Behavior: Effects of Selective Antagonists and Agonists J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 680 - 687. [Abstract] [Full Text] |
||||
![]() |
D. M. Platt, J. K. Rowlett, and R. D. Spealman Dissociation of Cocaine-Antagonist Properties and Motoric Effects of the D1 Receptor Partial Agonists SKF 83959 and SKF 77434 J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1017 - 1026. [Abstract] [Full Text] |
||||